|Bid||351.75 x 100|
|Ask||435.00 x 100|
|Day's Range||373.00 - 384.07|
|52 Week Range||340.09 - 543.55|
|PE Ratio (TTM)||34.53|
|Earnings Date||Jan 31, 2018 - Feb 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||458.78|
The Zacks Analyst Blog Highlights: Netflix, Stamps.com, Constellation Brands and Regeneron Pharmaceuticals
Amgen and Regeneron will battle in 2018 after the latter unveils cardiovascular data for its cholesterol drug Praluent.
In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety ...
In 3Q17, Regeneron Pharmaceuticals’ (REGN) Eylea generated revenue of $953 million, which reflected ~12% growth YoY (year-over-year) and 4% growth QoQ (quarter-over-quarter). In the first nine months of ...
In 3Q17, Regeneron Pharmaceuticals (REGN) generated revenue of $1.5 billion, which reflected ~23% growth year-over-year and ~2% growth quarter-over-quarter.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced Monday the failure and discontinuation of two trials for angiopoietin2. Between this and rising rivals, Regeneron bears are emerging. The Rating ...
Regeneron Pharmaceuticals Inc. Chief Executive Officer Leonard Schleifer took direct aim at a fellow CEO Thursday, saying that Allergan Plc’s recent attempt to defend a drug patent by transferring it to ...
Here's a look at the latest deal between Regeneron and Decibel and what it means for the company going forward.
While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.
Decibel Therapeutics Inc. has struck an unusual collaboration with Regeneron Pharmaceuticals Inc. aimed at boosting its odds of success in the notoriously difficult market for drugs to treat hearing loss....
TARRYTOWN, N.Y. and BOSTON, Nov. 29, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Decibel Therapeutics, Inc., today announced a collaboration to discover and develop new potential therapeutics to protect, repair, and restore hearing. Decibel is establishing a leadership position in hearing therapeutics by building the world's first comprehensive, integrated drug discovery, translational research, and drug development platform for hearing loss and tinnitus. Regeneron has established world-leading capabilities in genetics research, drug discovery, and antibody development and manufacturing, which can now be used in synergy with Decibel's efforts in hearing loss.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced results Monday from two mid-stage studies for diabetic macular edema and age-related macular degeneration therapies. The combo did not provide sufficient ...
Regeneron Pharmaceuticals (REGN) announced that it will not advance two mid-stage studies evaluating the combination of nesvacumab of Eylea to phase III.
Regeneron fell Monday after a combination of its eye medicine Eylea and a drug from Bayer failed in a pair of studies.
Regeneron Pharmaceuticals Inc. shares declined 2% in premarket trade Monday after the company said that results from two phase 2 trials studying its combination therapy did not support advancing the program ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Over the last one-month, outflows of investor capital in ETFs holding REGN totaled $735 million.
Dr. Leonard Schleifer, Regeneron CEO, speaks to CNBC's Meg Tirrell about the partnership with Decibel to combat hearing loss as well as the company's genetics research.